Boehringer Mannheim Gmbh

Roche Diagnostics Gmbh

Brigitte Kaluza

Helmut Lenz

Ulrich Weidle

Martin Kaufmann

Ulrich Bogdahn

Anja-Katrin Bosserhoff

Eberhard Russmann

Reinhard Buttner

Reinhard Burrner

Iise Bartke

Tiberiu Diamantstein

Klaus-Peter Hirth

Monoclonal antibodies against the interleukin 2 receptor

The subject matter of the present invention are high-affinity monoclonal antibodies against MIA (Melanoma inhibitory activity) in native conformation, which can be used for the detection of malignant melanomas, their use for the detection of MIA as well as immunoassays for the detection of MIA.

Immunoassay for the detection of MIA

Melanoma-inhibiting protein

Chimeric monoclonal antibodies or fragments thereof are used according to the present invention in diagnostic tests for the quantitative immunological determination of substances in the blood or serum of patients. For the diagnostic detection of substances in serum or blood of patients by binding of two monoclonal antibodies R.sub.1 and R.sub.2 directed against the substance, of which the first antibody R.sub.1 is capable of binding to a solid phase or is already bound and the second antibody R.sub.2 carries a label, binding of the antibody R.sub.1 to the solid phase if desired, separation of the complex formed of R.sub.1, substance and R.sub.2 which is bound to the solid phase and detection via the labelling of the antibody R.sub.2, a chimeric monoclonal antibody or a fragment thereof is used at least for one of the antibodies R.sub.1 or R.sub.2.

Diagnostic test using chimeric antibodies

Growing community of inventors

Bad Heilbrunn, Germany

Brigitte Kaluza